Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.

Hawman DW, Meade-White K, Haddock E, Habib R, Scott D, Thomas T, Rosenke R, Feldmann H.

J Virol. 2019 Aug 28;93(18). pii: e00554-19. doi: 10.1128/JVI.00554-19. Print 2019 Sep 15.

PMID:
31292241
2.

Recent advances in understanding Crimean-Congo hemorrhagic fever virus.

Hawman DW, Feldmann H.

F1000Res. 2018 Oct 29;7. pii: F1000 Faculty Rev-1715. doi: 10.12688/f1000research.16189.1. eCollection 2018. Review.

3.

Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice.

Hawman DW, Haddock E, Meade-White K, Williamson B, Hanley PW, Rosenke K, Komeno T, Furuta Y, Gowen BB, Feldmann H.

Antiviral Res. 2018 Sep;157:18-26. doi: 10.1016/j.antiviral.2018.06.013. Epub 2018 Jun 21.

PMID:
29936152
4.

A cynomolgus macaque model for Crimean-Congo haemorrhagic fever.

Haddock E, Feldmann F, Hawman DW, Zivcec M, Hanley PW, Saturday G, Scott DP, Thomas T, Korva M, Avšič-Županc T, Safronetz D, Feldmann H.

Nat Microbiol. 2018 May;3(5):556-562. doi: 10.1038/s41564-018-0141-7. Epub 2018 Apr 9.

5.

Mutations in the E2 Glycoprotein and the 3' Untranslated Region Enhance Chikungunya Virus Virulence in Mice.

Hawman DW, Carpentier KS, Fox JM, May NA, Sanders W, Montgomery SA, Moorman NJ, Diamond MS, Morrison TE.

J Virol. 2017 Sep 27;91(20). pii: e00816-17. doi: 10.1128/JVI.00816-17. Print 2017 Oct 15.

6.

Animal Models of Chikungunya Virus Infection and Disease.

Haese NN, Broeckel RM, Hawman DW, Heise MT, Morrison TE, Streblow DN.

J Infect Dis. 2016 Dec 15;214(suppl 5):S482-S487. Review.

7.

Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.

Hawman DW, Fox JM, Ashbrook AW, May NA, Schroeder KMS, Torres RM, Crowe JE Jr, Dermody TS, Diamond MS, Morrison TE.

Cell Rep. 2016 Aug 2;16(5):1326-1338. doi: 10.1016/j.celrep.2016.06.076. Epub 2016 Jul 21.

8.

Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.

Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS.

J Virol. 2014 Aug;88(15):8213-26. doi: 10.1128/JVI.01032-14. Epub 2014 May 14.

9.

Attenuating mutations in nsP1 reveal tissue-specific mechanisms for control of Ross River virus infection.

Stoermer Burrack KA, Hawman DW, Jupille HJ, Oko L, Minor M, Shives KD, Gunn BM, Long KM, Morrison TE.

J Virol. 2014 Apr;88(7):3719-32. doi: 10.1128/JVI.02609-13. Epub 2014 Jan 15.

10.

Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.

Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, Morrison TE.

J Virol. 2013 Dec;87(24):13878-88. doi: 10.1128/JVI.02666-13. Epub 2013 Oct 16.

11.

A tyrosine-to-histidine switch at position 18 of the Ross River virus E2 glycoprotein is a determinant of virus fitness in disparate hosts.

Jupille HJ, Medina-Rivera M, Hawman DW, Oko L, Morrison TE.

J Virol. 2013 May;87(10):5970-84. doi: 10.1128/JVI.03326-12. Epub 2013 Mar 20.

Supplemental Content

Loading ...
Support Center